Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 10/20 | 0.65 |
| ▸ | HDAC6 | Q9UBN7 | 9/20 | 0.65 |
| ▸ | IL1RN | P18510 | 1/20 | 0.48 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.48 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.48 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.40 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.40 |
| ▸ | PDE5A | O76074 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.39 |
| ▸ | LSS | P48449 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14322408 | 0.84 | HDAC8 (0.51) | HDAC8HDAC6HTR6CYP17A1HCRTR1 | |
| SCHEMBL16199217 | 0.81 | HDAC8 (0.58) | HDAC8HDAC6IL1RNERAP2ERAP1 | |
| SCHEMBL14324044 | 0.81 | HDAC8 (0.58) | HDAC8HDAC6IL1RNERAP2ERAP1 | |
| SCHEMBL14323042 | 0.79 | HDAC8 (1.00) | HDAC8HDAC6HTR6LSS | |
| SCHEMBL14322853 | 0.68 | HDAC8 (0.70) | HDAC8HDAC6IL1RNERAP2ERAP1 | |
| SCHEMBL216021 | 0.66 | CNR2 (0.54) | IL1RNERAP2ERAP1 | |
| SCHEMBL27976942 | 0.66 | PDE5A (0.59) | HDAC8HDAC6HTR6CYP17A1PDE5A | |
| SCHEMBL14322583 | 0.65 | HDAC8 (0.67) | HDAC8HDAC6 | |
| SCHEMBL14328260 | 0.65 | HDAC8 (1.00) | HDAC8HDAC6 | |
| SCHEMBL15804414 | 0.64 | CYP1A2 (0.50) | HDAC8HDAC6CYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8871728-B2 | Non-peptide macrocyclic histone deacetylese (HDAC) inhibitors and methods of making and using thereof | GEORGIA TECH RESEARCH CORPORATION (US) | 2014-10-28 | — | — | US | disclosed |
| US-20120329741-A1 | NON-PEPTIDE MACROCYCLIC HISTONE DEACETYLASE (HDAC) INHIBITORS AND METHODS OF MAKING AND USING THEREOF | GEORGIA TECH RESEARCH CORPORATION | 2012-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329741-A1 | NON-PEPTIDE MACROCYCLIC HISTONE DEACETYLASE (HDAC) INHIBITORS AND METHODS OF MAKING AND USING THEREOF | HDAC5, HDAC3, HDAC1 | HDAC8 9/4885HDAC6 11/4885IL1RN 2916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.